Literature DB >> 15047550

In vitro antimicrobial activity of doripenem, a new carbapenem.

Yigong Ge1, Matthew A Wikler, Daniel F Sahm, Renée S Blosser-Middleton, James A Karlowsky.   

Abstract

The doripenem MICs at which 90% of the tested strains were inhibited ranged from 0.03 to 1 microg/ml for 10 species of Enterobacteriaceae (n = 351), from 0.03 to 0.12 microg/ml for oxacillin-susceptible staphylococci (n = 119), from 4 to 32 microg/ml for oxacillin-resistant staphylococci (n = 64), from < or =0.008 to 0.06 microg/ml for penicillin-susceptible streptococci (n = 132), and from 1 to 4 microg/ml for penicillin-resistant streptococci (n = 51). Overall, doripenem demonstrated in vitro activity similar to that of meropenem against gram-negative pathogens and to that of imipenem against gram-positive pathogens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047550      PMCID: PMC375337          DOI: 10.1128/AAC.48.4.1384-1396.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens.

Authors:  A Watanabe; H Takahashi; T Kikuchi; T Kobayashi; K Gomi; S Fujimura; Y Tokue; T Nukiwa
Journal:  Chemotherapy       Date:  2000 May-Jun       Impact factor: 2.544

2.  In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections.

Authors:  S Nomura; A Nagayama
Journal:  J Chemother       Date:  2002-04       Impact factor: 1.714

3.  In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.

Authors:  P J Petersen; N V Jacobus; W J Weiss; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

4.  Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I.

Authors:  M Mori; M Hikida; T Nishihara; T Nasu; S Mitsuhashi
Journal:  J Antimicrob Chemother       Date:  1996-05       Impact factor: 5.790

5.  In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem.

Authors:  K Yamaguchi; H Domon; S Miyazaki; K Tateda; A Ohno; K Ishii; T Matsumoto; N Furuya
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.

Authors:  M Tsuji; Y Ishii; A Ohno; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

7.  In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem.

Authors:  F Ohba; M Nakamura-Kamijo; N Watanabe; K Katsu
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

8.  A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems.

Authors:  Y Iso; T Irie; Y Nishino; K Motokawa; Y Nishitani
Journal:  J Antibiot (Tokyo)       Date:  1996-02       Impact factor: 2.649

9.  Antimicrobial-induced release of endotoxin from Pseudomonas aeruginosa: comparison of in vitro and animal models.

Authors:  Masakatsu Tsuji; Hayato Matsuda; Hideaki Miwa; Shuichi Miyazaki
Journal:  J Antimicrob Chemother       Date:  2003-02       Impact factor: 5.790

  9 in total
  27 in total

1.  Comparison of broth microdilution, agar dilution, and Etest for susceptibility testing of doripenem against gram-negative and gram-positive pathogens.

Authors:  K Amsler; C Santoro; B Foleno; K Bush; R Flamm
Journal:  J Clin Microbiol       Date:  2010-06-30       Impact factor: 5.948

2.  Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem.

Authors:  Sujata M Bhavnani; Jeffrey P Hammel; Brenda B Cirincione; Matthew A Wikler; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

3.  Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates.

Authors:  C Betriu; M Gómez; F López-Fabal; E Culebras; I Rodríguez-Avial; J J Picazo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-04       Impact factor: 3.267

4.  Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.

Authors:  Karen E Bowker; Alan R Noel; Sharon G Tomaselli; Heather Elliott; Alasdair P Macgowan
Journal:  Antimicrob Agents Chemother       Date:  2012-06-19       Impact factor: 5.191

5.  Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.

Authors:  Anne Marie Queenan; Wenchi Shang; Robert Flamm; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

6.  Activities of doripenem (S-4661) against drug-resistant clinical pathogens.

Authors:  Ronald N Jones; Holly K Huynh; Douglas J Biedenbach
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

7.  Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.

Authors:  Koichi Tanimoto; Haruyoshi Tomita; Shuhei Fujimoto; Katsuko Okuzumi; Yasuyoshi Ike
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

Review 8.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Doripenem (Doribax): the newest addition to the carbapenems.

Authors:  Nickie D Greer
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-07

10.  Characteristics of doripenem: a new broad-spectrum antibiotic.

Authors:  Francisco Alvarez-Lerma; Santiago Grau; Olivia Ferrández
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.